指南与共识乳腺癌

晚期乳腺癌基因检测中国临床实践指南(2025版)

[Chinese clinical practice guideline for genetic testing in advanced breast cancer (2025 edition)].
指南 / 共识 · Zhonghua Zhong Liu Za Zhi · 2025-01-01

中国抗癌协会乳腺癌专业委员会牵头多学科工作组,按预设方法学流程制定本指南,针对晚期乳腺癌基因检测的适用人群、标本选择、检测技术与目标基因选择提出具体推荐,并梳理不同基因变异可选的靶向治疗策略,综合循证证据等级与药物可及性进行分级。

要点

  • 指南针对晚期乳腺癌基因检测的适用人群、标本选择、检测技术与目标基因选择提出推荐。
  • 系统梳理不同基因变异可选的靶向治疗策略并按证据等级与药物可及性分级。
  • 强调检测可行性与结果可操作性,旨在衔接精准检测与个体化靶向治疗。

核心结论

  • 指南就中国晚期乳腺癌患者基因检测标准化路径达成多学科共识,为提升规范化诊疗水平提供实用依据。

研究设计与样本

  • 中国抗癌协会乳腺癌专业委员会牵头组建多学科工作组制定本指南。
  • 制定流程包括临床问题遴选、系统证据检索、分级评价与推荐意见形成。

主要发现

  • 转移性乳腺癌基因组具有时空异质性并可能动态演变。
  • 基因检测结果指导下的靶向治疗是改善患者生存结局的重要手段。

关键数值与推荐

  • 指南针对晚期乳腺癌基因检测的适用人群、标本选择、检测技术与目标基因选择提出具体推荐。
  • 指南系统梳理不同基因变异可选的靶向治疗策略,并综合循证证据等级与药物可及性进行分级。

临床怎么用

  • 临床可参照指南推荐对晚期乳腺癌患者开展规范化基因检测。
  • 可依据基因变异类型及指南分级选择相应靶向治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Breast cancer is one of the most common malignancies among women in China. According to GLOBOCAN 2022, more than 350,000 new breast cancer cases were diagnosed in China, ranking second among all newly diagnosed cancers in women. Although breast cancer has entered an era of chronic disease management and overall survival has improved substantially, the prognosis of metastatic breast cancer (MBC) remains unsatisfactory. The genome of MBC is characterized by spatiotemporal heterogeneity and may undergo dynamic evolution. With the continuous identification of actionable alterations, targeted therapies guided by genomic testing have emerged as an important approach to improving patient outcomes. Therefore, the implementation of standardized genomic testing in clinical practice has become an urgent priority. While several international and domestic guidelines have recommended genomic testing for MBC, China still lacks detailed technical specifications and clinical pathways tailored to advanced disease in the local healthcare context. Accordingly, it is imperative to establish a guideline for genomic testing in advanced breast cancer that reflects national realities, ensures strong clinical operability, unifies testing standards, and optimizes workflows, thereby expanding access to precision therapy and improving patient prognosis. Against this background, the Breast Cancer Committee of the Chinese Anti-Cancer Association convened a multidisciplinary working group experts. Following predefined methodological procedures-including clinical question prioritization, systematic evidence retrieval, graded evaluation, and formulation of recommendations-the guideline was developed. It integrates the latest evidence with multidisciplinary expert consensus, providing specific recommendations on key aspects of genomic testing for MBC, including patient eligibility, specimen selection, testing methodologies, and prioritization of target genes. In addition, the guideline systematically summarizes available targeted therapeutic strategies for different genomic alterations, and provides graded recommendations based on both levels of evidence and drug accessibility, thereby ensuring clarity and facilitating clinical implementation. This guideline is closely aligned with the realities of clinical practice and drug accessibility in China, with a strong emphasis on the feasibility of testing and the actionability of results. It establishes a multidisciplinary consensus on standardized pathways for genomic testing in patients with MBC, aiming to bridge precision diagnostics and individualized targeted therapy, and to provide practical guidance for improving the standardization of advanced breast cancer care nationwide. 乳腺癌是中国女性常见的恶性肿瘤之一。2022年GLOBOCAN数据显示,中国新发乳腺癌病例数超过35万例,其发病率在中国女性新发肿瘤中位居第2位。尽管乳腺癌正在进入慢病化管理时代,整体生存率取得了长足进步,但转移性乳腺癌的预后仍不理想。转移性乳腺癌的基因组具有时空异质性并可能发生动态演变,随着可靶向突变的不断发现,基因检测结果指导下的靶向治疗逐渐成为改善患者生存结局的重要手段,在临床实践中推行规范化的基因检测已成为当前亟待推进的重要任务。目前,多部国际与国内的乳腺癌诊疗指南已明确推荐对转移性乳腺癌进行基因检测,但国内尚缺乏针对晚期阶段基因检测在中国临床环境下的详细技术规范和临床路径指导。因此,亟需制定一部符合中国国情、具有较强临床可操作性的晚期乳腺癌基因检测指南,以统一检测标准、优化检测流程,进一步提升精准治疗的覆盖范围与患者预后。中国抗癌协会乳腺癌专业委员会牵头组建的多学科工作组,根据预设的方法学流程,经过临床问题遴选、系统证据检索、分级评价与推荐意见形成等步骤,最终完成指南的制定。晚期乳腺癌基因检测临床应用指南(2025版)系统整合了最新循证与跨学科专家意见,针对晚期乳腺癌基因检测的适用人群、标本选择、检测技术与目标基因选择等关键环节提出具体推荐意见;同时,系统梳理了不同基因变异可选的靶向治疗策略,并在综合循证证据等级与药物可及性基础上进行了分级,使推荐更加明确并便于临床实践。指南紧密结合中国临床实际与药物可及性现状,注重检测可行性和结果可操作性,就国内晚期乳腺癌患者基因检测的标准化路径达成多学科共识,旨在推动精准检测与个体化靶向治疗间的衔接,为提升中国晚期乳腺癌规范化诊疗水平提供实用依据。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Chinese clinical practice guideline for genetic testing in advanced breast cancer (2025 edition)]. Zhonghua Zhong Liu Za Zhi. 2025. PMID: 41130778. doi:10.3760/cma.j.cn112152-20250618-00279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。